Metalloprotein Inhibitors for the Treatment of Human Diseases.
Metalloproteins have attracted momentous attentions for the treatment of many human diseases, including cancer, HIV, hypertension, etc. This article reviews the progresses that have been made in the field of drug development of metalloprotein inhibitors, putting emphasis on the targets of carbonic anhydrase, histone deacetylase, angiotensin converting enzyme, and HIV-1 integrase. Many other important metalloproteins are also briefly discussed. The binding and coordination modes of different marketed metalloprotein inhibitors are stated, providing insights to design novel metal binding groups and further novel inhibitors for metalloproteins.
Yang
Y
Yang
Xue-Qin
XQ
Hu
Qing-Shan
QS
Li
Xing-Xing
XX
Zhang
Ban-Feng
BF
Ruan
Jun
J
Xu
School of Medical Engineering, Hefei University of Technology, Hefei 230009, P.R. China. czliao@hfut.edu.cn.
Chenzhong
C
Liao
D015658:HIV Infections / Q000188:drug therapy*; D006801:Humans; D006973:Hypertension / Q000188:drug therapy*; D008667:Metalloproteins / Q000037:antagonists & inhibitors* / Q000378:metabolism; D008958:Models, Molecular; D015394:Molecular Structure; D009369:Neoplasms / Q000188:drug therapy*; D011480:Protease Inhibitors / Q000737:chemistry / Q000494:pharmacology* / Q000627:therapeutic use; D013329:Structure-Activity Relationship
D008667:Metalloproteins; D011480:Protease Inhibitors